摘要
BCR-ABL1酪氨酸激酶抑制剂(TKI)可显著改善慢性粒细胞白血病(CML)患者的生存及预后。但长期服用TKI存在药物不良反应、降低患者生命质量及增加经济负担等问题。因此,CML患者达到一定疗效标准后能否成功停药成为人们关注的焦点。目前,无治疗缓解(TFR)逐渐成为CML治疗的新目标。多项临床研究证实了TFR在特定患者人群中的可行性和安全性,TFR现已纳入临床指南。文章将结合CML患者追求TFR的主要原因及实现TFR的可能机制等问题进行阐述。
Tyrosine kinase inhibitor(TKI)targeting BCR-ABL1 has significantly improved the survival and prognosis of patients with chronic myeloid leukemia(CML).However,long-term treatment with TKI has caused many problems like adverse drug reactions,decreasing the quality of patients'life and increasing financial burden.Therefore,whether CML patients can successfully stop taking TKI after reaching a certain therapeutic standard has become a matter of concern.At present,treatment-free remission(TFR)has already become a new target for CML therapy.Several clinical trials have confirmed the feasibility and safety of TFR in specific patient populations,and TFR is now incorporated into clinical guidelines.This paper reviews the main reasons for CML patients'pursuit of TFR and the possible mechanisms of TFR.
作者
邹忠晴
杨云帆
张丽
潘崚
Zou Zhongqing;Yang Yunfan;Zhang Li;Pan Ling(Department of Hematology,West China Hospital,Sichuan University,Chengdu 610041,China)
出处
《白血病．淋巴瘤》
CAS
2020年第6期371-374,共4页
Journal of Leukemia & Lymphoma
作者简介
通信作者:潘崚,Email:lingpan20002000@aliyun.com。
